Establishment and characterization of a pancreatic carcinoma cell line derived from malignant pleural effusion

Oncology

Volumn 69, Issue 3, 2005, Pages 239-245

  Starr, A N ^a   Vexler, A ^a   Marmor, S ^a   Konik, D ^a   Ashkenasi Voghera, M ^a   Lev Ari, S ^a   Greif, Y ^a   Ben Yosef, R ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Chemoradiotherapy; p34 cell line; Pancreatic cancer

Indexed keywords

CELECOXIB; CISPLATIN; CURCUMIN; GEMCITABINE; NAVELBINE; PACLITAXEL;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL CYCLE; CELL PROLIFERATION; CHROMOSOME 2; CONTROLLED STUDY; GENE DUPLICATION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; KARYOTYPE; METASTASIS; PANCREAS CARCINOMA; PLEURA EFFUSION; PRIORITY JOURNAL;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOGENICITY TESTS; CELL CYCLE; CELL LINE, TUMOR; CHEMOTHERAPY, ADJUVANT; COLORIMETRY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INDICATORS AND REAGENTS; KARYOTYPING; MICE; MICE, NUDE; MIDDLE AGED; PANCREATIC NEOPLASMS; PLEURAL EFFUSION, MALIGNANT; PLOIDIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; TETRAZOLIUM SALTS; TRANSPLANTATION, HETEROLOGOUS;

EID: 26444507147     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000088071     Document Type: Article

References (24)

1. American Cancer Society: Cancer Facts and Figures. Atlanta, American Cancer Society Press, 2003, p 16.
2. Warshaw AL, Fernandez-del Castillo C: Pancreatic carcinoma. N Engl J Med 1992;326:455-465.
3. Evans DB, Abbruzzese JL, Rich TR: Cancer of the pancreas; in deVita VT, Hellman S, Rosenberg SA (eds): Cancer Principles and Practice of Oncology. New York, Lippincott, 1997, vol 5, pp 1054-1087.
4. Wanebo HJ, Vezeridis MP: Pancreatic carcinoma in perspective: A continuing challenge. Cancer 1996;78:580-591.
5. Fernandez E, La Vecchia C, Porta M, Negri E, Lucchini F, Levi F: Trends in pancreatic cancer mortality in Europe, 1955-1989. Int J Cancer 1994;57:786-792.
6. Bardeesy N, Depinho RA: Pancreatic cancer biology and genetics. Nat Rev 2002;2:897-909.
7. Abbruzzese JL: New application of gemcitabine and future directions in the management of pancreatic cancer. Cancer 2002;95:941-945.
8. Gansauge S, Gansauge F, Beger HG: Molecular oncology in pancreatic cancer. J Mol Med 1996;74:313-320.
9. Staroselsky A, Pathak S, Fidler IJ: Changes in clonal composition during in vivo growth of mixed subpopulations derived from the murine K-1735 melanoma. Anticancer Res 1990;10:291-296.
10. Pathak S, Staroselsky AN, Fidler IJ: Specific chromosomal defects associated with metastatic potential in K-1735 melanoma clones. Involvement of chromosomes 4 and 14. Cancer Genet Cytogenet 1991;56:209-221.
11. Gorodetsky R, Levdansky L, Ringel I, Vexler A: Paclitaxel-induce modification of the effects of radiation and alterations in the cell cycle in normal and tumor mammalian cells. Radiat Res 1998;150:283-291.
12. Staroselsky A, Fan D, O'Brian CA, Bucana CD, Gupta KP, Fidler I.J.: Site-dependent differences in response of the UV-2237 murine fibrosarcoma to systemic therapy with adriamycin. Cancer Res 1990;50:7775-7780.
13. Vila MR, Lloreta J, Schussler MH, Berrozpe G, Welt S, Real FX: New pancreas cancers cell lines that represent distinct stages of ductal differentiation. Lab Invest 1995;72:395-404.
14. Elsasser HP, Lehr U, Agricola B, Kern HF: Structural analysis of a new highly metastatic cell line PaTu 8902 from a primary human pancreatic adenocarcinoma. Virchows Arch B Cell Pathol Incl Mol Pathol 1993;64:201-207.
15. Rafiee P, Ho SB, Bresalier RS, Bloom EJ, Kim JH, Kim YS: Characterization of the cytokeratins of human colonic, pancreatic, and gastric adenocarcinoma cell lines. Pancreas 1992;7:123-131.
16. Kato M, Shimada Y, Tanaka H, Hosotani R, Ohshio G, Ishizaki K, Imamura M: Characterization of six cell lines established from human pancreatic adenocarcinomas. Cancer 1999;85:832-840.
17. Frazier ML, Fernandez E, de Llorens R, Brown NM, Pathak S, Cleary KR, Abbruzzese JL, Berry K, Olive M, Le Maistre A, Evans DB: Pancreatic adenocarcinoma cell line, MDAPanc28, with features of both acinar and ductal cells. Int J Pancreatol 1996;1:31-38.
18. Heike M, Rohrig O, Gabbert HE, Moll R, Meyer zum Buschenfelde KH, Dippold WG, Knuth A: New cell lines of gastric and pancreatic cancer: Distinct morphology, growth characteristics, expression of epithelial and immunoregulatory antigens. Virchows Arch 1995;426:375-384.
19. Adsay NV, Dergham ST, Koppitch FC, Dugan MC, Mohamed AN, Vaitkevicius VK, Sarkar FH: Utility of fluorescence in situ hybridization in pancreatic ductal adenocarcinoma. Pancreas 1999;18:111-116.
20. Ghadimi BM, Schrock E, Walker RL, Wangsa D, Jauho A, Meltzer PS, Ried T: Specific chromosomal aberrations and amplification of the A1B1 nuclear receptor coactivator gene in pancreatic carcinomas. Am J Pathol 1999;154:525-536.
21. Zojer N, Fiegl M, Mullauer L, Chott A, Ackermann J, Raderer M, Kafmann H, Reiner A, Huber H, Drach J: Chromosomal imbalances in primary and metastatic pancreatic carcinoma as detected by interphase cytogenetics: Basic finding and clinical aspects. Br J Cancer 1998;77:1337-1342.
22. Sato N, Mizumoto K, Maehara N, Shono M, Nagai E, Tanaka M: Instability of chromosome 8 as an indicator of aggressive tumor phenotype in pancreatic cancer. J Surg Oncol 2001;76:181-187.
23. Gupta RA, DuBois RN: Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001;1:11-21.
24. Aggarwal BB, Kumar A, Bharti AC: Anticancer potential of curcumin: Preclinical and clinical studies. Anticancer Res 2003;23:363-398.